Safety and efficacy of dual CD19/CD22 targeted chimeric antigen receptor T cells for hematological malignancies

Conditions

hematological malignancies

Shuyang Wang, Qian Wu, Mengmeng Huang, Mingming Zhang, Shan Fu et al. (12 authors)

Blood2025-11-03

10.1182/blood-2025-2381

Clinical manifestations, risk factors and prognosis associated with central nervous system relapse after CAR-T therapy for R/R B-cell non-Hodgkin lymphoma: A multi-center analysis

Tianning Gu, Tingting Yang, Mengyu Zhao, Yetian Dong, Meng Zhu et al. (17 authors)

Blood2025-11-03

10.1182/blood-2025-6340

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Mengyu Zhao, Tingting Yang, Yetian Dong, Wenxiao Li, Tianning Gu et al. (14 authors)

Blood2023-11-02

10.1182/blood-2023-187951

Interventions

Case series:YK-CD19-22-BoomTM infusion

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: 1. Relasped or refractory hematological malignancies with CD19 and CD22 positive; 2. Expected life time is more than 12 weeks; 3. urine pregnancy test negative; 4. Voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. patients with the history of epilepsy or other CNS disease; 2. patiets with GVHD who need immunosuppressive agents; 3. Patients with prolonged QT interval time or severe heart disease; 4. Patients with active hepatitis B or C infection; 5. patients with HIV infection.

Design outcomes

Primary

Measure	Time frame
Complete remission rate;	—

Secondary

Measure	Time frame
Non relapse mortality;	—

Countries

China

Contacts

Public ContactHe Huang

the First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed